के सभी प्रकाशन Diksha Pote . पुणे , भारत

Publications

Carrier Screening Market Key Developments Trends, Analysis and Forecasts Till 2027


Market Highlights

According to MRFR analysis, the Global Carrier Screening Market is expected to register a CAGR of 16.8% during the forecast period of 2019 to 2025 and is anticipated to reach USD 4,200 Million by 2025.

The growth of the global carrier screening market is driven by various factors, such as the increasing launch of carrier screening products and growing numbers of players involved in the development of new carrier screening technologies. Some of the key companies operating in this market are Eurofins Scientific, Invitae Corporation, Illumina Inc, Luminex Corporation and others. In addition, the rising awareness program about genetic disorders supports the Carrier Screening Market growth during the forecasted period.

However, the lack of skilled professionals and accuracy issues of carrier screening products may hamper market growth.

Key Players

Some of the key players in the Global Carrier Screening Market are Eurofins Scientific (Luxembourg), Invitae Corporation (US), Opko Health (US), Fulgent Genetics Inc (US), Quest Diagnostics Incorporated (US), Sema4 (US), Myriad Genetics (US), Illumina Inc (US), Thermo Fisher Scientific Inc (US), Luminex Corporation (US), Natera Inc (US) and Laboratory Corporation of America Holdings (US).

Segmentation

The Global Carrier Screening Market has been segmented based on Product & Service, Type, Medical Condition, Technology, and End Users.

The market, based on product & service, has been divided into products and services. The product segment is likely to hold the largest during the review period as it is the most common and available across the globe. Services are predicted to be the fastest-growing segment due to the growing number of laboratories adopting the carrier screening products.

The global carrier screening market has been segmented, on the basis of type, into expanded carrier screening and targeted disease carrier screening. The expanded carrier screening segment is expected to hold the maximum share of the market throughout the forecast period. The targeted disease carrier screening segment is expected to be the fastest-growing during the assessment period. Based on medical conditions, the market is segmented into pulmonary conditions, hematological conditions, neurological conditions, and others. By technology, the market has been segmented into a polymerase chain reaction, microarrays, and others. On the basis of end-user, the market is segmented into hospitals, reference laboratories, physician offices, and clinics and others.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the increased awareness about genetic disorders and its diagnosis methods. The carrier screening market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.

The high occurrence of inherited diseases such as sickle cell anemia, X linked disorders and among other disorders in the US is one of the reasons for the growth of the market in the country. The European carrier screening market is the fastest-growing market, and it has been categorized as Western Europe and Eastern Europe. The Western European market has further been divided as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The increasing healthcare expenditure is one of the factors pushing the growth of the regional market. The carrier screening market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the rising per capita income, growing healthcare expenditure and awareness towards the diagnosis of genetic diseases during pregnancy drives the market to grow at a significant rate during the forecast. The carrier screening market in the Middle East & Africa has been divided into the Middle East and Africa.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America


Show more
0
7

Hemostasis and Tissue Sealing Agents Market Value Chain, Factor Analysis, Region and Forecasts Till 2027


Market Highlights

The global hemostasis and tissue sealing agents market is projected to grow at a CAGR of 8.6% over the forecast period. There has been increasing demand for such products as it reduces complication during surgical procedures. Moreover, large number of surgical procedures across the globe are impacting the growth of the market positively. Increasing numbers of surgery procedures worldwide is one of another reason for driving the growth of the hemostasis and tissue sealing agents market. Surgeries are performed by making cut on the body which leads to the wound formation. Hemostasis and tissue sealing agents products are used in external surgical processes for reducing bleeding. For example, they are used in neurosurgical procedures, cardiac surgery, bariatric surgery, leg surgery, cesarean and orthopedic surgery. Hemostasis and tissue sealing agents products, are frequently used to reduce complexity and reduce recovery time after surgery. The high surgical procedure numbers lead to rising need for hemostasis and tissue sealing agents which reduces the risk during surgical procedures. However, factors such as increasing advancement minimally invasive procedures, lack of reimbursement for these products is hampering the growth of the market.

Key Players

Some of the prominent players in the global hemostasis and tissue sealing agents market are Johnson & Johnson, Cryolife, Inc., Baxter International, Inc, Ethicon LLC, Integra Lifesciences Corporation, Becton, Dickinson & Company, Cohera Medical, Inc., Pfizer, Inc, Medtronic plc, B. Braun Melsungen AG, MIL Laboratories Pvt. Ltd, Advanced Medical Solutions Group Plc and others.

Segmentation

The global hemostasis and tissue sealing agents market has been segmented into product, and end user.

By product, the market has been segmented into topical hemostats, and adhesive & tissue sealant. Furthermore, topical hemostats is divided into Active, mechanical (collagen based hemostats, cellulose based hemostats, gelatin based hemostats, polysaccharide based hemostats) Flowable. Adhesive & tissue sealant is further segmented into synthetic, natural, and adhesion barrier.

Further on the basis of end user the market is bifurcated into hospitals, ambulatory centers and others

Regional Analysis

Geographically, the Americas is anticipated to dominate the global hemostatic agent market owing to the high clinical R&D budgets by both government as well as public and private organizations, presence of major manufacturers for the products, high number of surgical procedures and various others. For instance, according to the Center for Diseases Control and Prevention, approximately 46.5 million surgical procedures are performed every year in the U.S.

Europe is expected to hold the second largest position in the global hemostasis and tissue sealing agents market. The Hemostasis and tissue sealing agents market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to increased medical tourism for surgical procedures, increasing healthcare expenditure in developing countries and various others. The Middle East & Africa has the lowest share of the global hemostasis and tissue sealing agents market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of Americav

Show more
0
7

Lupus Market Key Manufactures Shares, Analysis and Forecasts Till 2027


Overview:

Lupus is a chronic autoimmune disease which occurs when the immune system attacks the healthy cells and tissues of the body, thereby causing inflammation, pain, swelling, and damage throughout the body. Many people have an inherit tendency towards developing or attaining lupus, which can be triggered due to certain drugs, infections, or even sunlight. The prevalence of this condition has prompted Market Research Future (MRFR) to take notice and study the global market of the same. As of 2022, the market valuation of Lupus stood at USD 1.48 billion. However, as per the latest studies, the global lupus market is projected to grow significantly during the forecast period with a CAGR of 11.2%.


Various factors such as the growing prevalence of lupus diseases, increasing R&D activities, and continuing medical advancements for the treatment of systemic lupus symptoms erythematosus are all identified as key factors driving the growth of the market. Also, the market involves a number of noteworthy companies that are involved in the development of new products and product launches. However, irrespective of the market drivers, constraints such as strict government regulation and rising prices of lupus drugs can severely hamper its market growth during the review period.

Competitive Landscape

The global lupus market holds a number of noteworthy players, including Merck KGaA, Cadila Healthcare, Mylan N.V., F. Hoffmann-La Roche AG, Aurinia Pharmaceuticals, Inc., GlaxoSmithKline PLC, Eli Lily and Company, Pfizer, Inc., Bristol-Myers Squibb Company, Lycera Corporation, and Sanofi.

Dec 11th,, Neovacs, a pioneer in the field of active immune therapy for treating autoimmune diseases, announced the continuation of its partnership with Centurion Pharma in Lupus (SLE). This is based on the study results of the Phase IIb trial with IFNalpha Kinoid.

Market Segmentation

The Lupus Market segmentation is done on the basis of treatment, end-user, and types.

By treatment, the market includes antimalarial drugs, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), biologics, immunosuppressants, and others.

By end-user, the market divides into diagnostic laboratories, hospitals and clinics, and others.

Lastly, by type, the market comprises cutaneous lupus erythematosus, systemic lupus erythematosus, neonatal lupus, and drug-induced lupus erythematosus. The lupus erythematosus market segment is projected to hold the largest market percentage due to the increasing prevalence of such diseases and the increasing drug development over the years.

Regional Analysis

The global lupus market is geographically segmented into the following regions: Americas, Asia Pacific, Europe, and the Middle East & Africa.

The Americas is anticipated to be the most dominant regional market due to a number of factors. This includes the growing prevalence of lupus diseases, rising demand for better treatment options, favorable government initiatives, and the availability of reimbursement. In addition to these, the established healthcare infrastructure facility coupled with the accessibility to biologics are also expected to propel the market growth of this region.


The European market is believed to hold the second-largest market position following the Americas. The growth of the market herein is attributed to the expanding R&D activities and widespread prevalence of lupus diseases.

The Asia-Pacific region is expected to be the fastest-growing regional market. This can be attributed to the growing healthcare sector, the rising incidences of lupus diseases, and increasing regional expansion by prominent market players.

The Middle East & Africa region holds the least market share among all the mentioned regions.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

Show more
0
7
Show more